Status:
COMPLETED
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Eligibility:
All Genders
18-30 years
Brief Summary
This was a Retrospective cohort study based on the PMSI data source
Detailed Description
A retrospective database analysis was performed using the French national hospital claims database (Medicalized Information System Program - PMSI, 2015-2019), which includes discharge summaries for al...
Eligibility Criteria
Inclusion
- Patients treated with CAR-T cells from 2017 to 2019 and informed as such in the PMSI And
- Patients diagnosed with ALL or DLBCL when administering CAR-T cells and
- up to 25 years for patients with ALL
Exclusion
- All patients treated outside the two types of indications presented in the inclusion criteria will be excluded
Key Trial Info
Start Date :
December 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 28 2021
Estimated Enrollment :
273 Patients enrolled
Trial Details
Trial ID
NCT05349201
Start Date
December 9 2020
End Date
May 28 2021
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936-1080